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Abstract
γ-Secretase inhibitors are new anti-cancer agents targeting Notch
signaling. Their specificity for Notch is as yet unclear. Han and
colleagues investigated the effects of Z-LeuLeuNleu-CHO on
growth of breast cancer cells. The results demonstrated a
reduction in cell viability primarily via proteasome inhibition inde-
pendent of Notch activity. Currently, γ-secretase inhibitors in
clinical trials are structurally distinct from Z-LeuLeuNleu-CHO.
Their effects on the proteasome are yet to be determined.
However, findings from Han and colleagues pose two critical
questions: Is the level of proteasomal activity in breast tumors the
driving force for growth? What does the Notch pathway contribute
to this growth?
Breast cancer continues to be the second leading cause of
cancer-related deaths among women. In a recent article in
Breast Cancer Research, Han and colleagues investigated
the effects of γ-secretase inhibitor (GSI)-I on growth of
genetically different breast cancer cells [1].
Along with GSIs, current therapeutic strategies are
increasingly promising – particularly those targeted at ErbB-2
(HER2+)-positive or estrogen receptor alpha (ERα+)-positive
breast tumors. Triple-negative (HER2-negative, ERα-negative,
and progesterone receptor-negative) or basal-like breast
cancers lack targeted treatment, demonstrating the highest
mortality rate and overall reduced disease-free survival [2].
Emerging treatment approaches to help increase overall
patient survival lie in targeting novel pathways for the specific
subtypes of breast cancer. New chemotherapeutics aim at
targeting the Notch signaling pathway, one of the develop-
mental cell-to-cell contact transmembrane proteins involved
in cell fate determination, in cell differentiation, in cell
proliferation, and possibly in tumor-initiating cells [3]. Notch-1
and its ligand, Jagged-1, have been shown to be co-
overexpressed in breast cancer and to be correlated with the
poorest overall survival [4], and thus the signaling pathway
has surfaced as a potential therapeutic target.
The Notch pathway has a critical cleavage step involving a
complex of four proteins called the γ-secretase complex.
Enzymatic cleavage of Notch by the γ-secretase complex, the
third proteolytic cleavage in the pathway, is essential for the
formation of the active intracellular Notch domain: this is
therefore a desirable step for targeted inhibition. GSIs are still
in their infancy, leaving desired mechanistic effects necessary
to elucidate.
In the previous issue of Breast Cancer Research, Han and
colleagues investigated the targeted effects of GSI-I [1].
Their findings using GSI-I, a drug aimed at inhibiting the
Notch pathway, demonstrated cell death independent of
Notch – uncovering the proteasome as its main target. The
effects of GSIs recently developed and/or used in clinical
trials are currently being studied to understand their action on
breast cancer cell death. Similarly, proteasome inhibitors are
a recent line of anticancer drugs that have been shown to
cause cancer cell death and are still currently being
investigated [5].
Using several breast cancer cell lines, Han and colleagues
demonstrated that common GSIs such as DAPT and
L-685,458 inhibited γ-secretase and intracellular Notch
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domain formation, but had no effect on cell viability and
death. With Z-LeuLeuNleu-CHO (GSI-I), however, they were
able to induce cell death via proteasomal inhibition and
reduce  γ-secretase activity. Interestingly, they observed no
apparent effects of DAPT or L-685,458 on the proteasome.
The authors therefore concluded that Z-LeuLeuNleu-CHO
promoted cell death predominantly through proteasome
inhibition. In contrast, a study by Farnie and colleagues found
that DAPT reduced mammosphere formation by 22%
compared with vehicle [6]. In accordance, Meurette and
colleagues demonstrated that DAPT reduced Akt phosphory-
lation in MCF-7 and DCIS cell lines and increased sensitivity
to the chemotherapeutic class of nitrogen mustard alkylating
agents, known as melphalan (Alkeran) [7]. These studies
indicate that DAPT inhibited tumor-initiating breast cancer
cell growth and increased sensitivity to chemotherapeutic
agents. The importance of inhibiting the Notch pathway might
therefore be context dependent.
The authors do comment on the discrepancies of their
findings compared with previous published literature on the
basis of employing different experimental strategies. GSI-I
induced G2/M arrest and apoptosis in breast cancer cell lines
with effects on both γ-secretase activity and the proteasome
[8]. In agreement with Han and colleagues’ results, similar
studies indicated that GSI-I inhibits HER2-overexpressing
breast tumor-initiating sphere formation, which was not
apparent in MCF-7 cells that express low to moderate levels
of HER2 [9]. Interestingly, Han and colleagues showed that
proteasome inhibition using lactacystin reduced cell viability
in ERα–SKBr3 cells and MDA-MB-231 cells, with little effect
on ERα+MCF-7 cells. Could this observation suggest that the
level of proteasome activity differs between breast cancer
subtypes and that the degree to which GSI-I functions as a
proteasome inhibitor would depend on high proteasome
activity? With this in mind, their novel findings unfurled a
potential mechanism that could be advantageous.
Han and colleagues’ results could suggest a potential duality
in therapeutic treatment of breast cancer cells. Proteasome
inhibition could be a vital target of treatment in combination
with other oncogenic or growth-promoting proteins. Evidence
suggests the importance of inhibiting the Notch pathway in
combination with current targeting of ERα [10] or HER2 [11].
For example, recent studies have shown that GSI-I or
Ly 411,575 treatment of triple-negative MDA-MB-231 cells or
treatment in combination with tamoxifen in ERα+T47D:A18
cells arrested growth and caused tumor regression in vivo,
respectively [10]. In the HER2+ breast cancer cell line,
BT474, Ly 411,575 or MRK-003 GSI treatment increased
apoptosis and re-sensitized resistant HER2+ cells to
trastuzumab [12]. Furthermore, these two studies showed
that specific knockdown of Notch-1 by siRNA inhibited cell
proliferation and increased sensitivity to either 4-hydroxy-
tamoxifen or trastuzumab. These articles demonstrated the
importance of Notch-1 signaling in ERα–, ERα+, or HER2+
breast cancer cells [10,12]. GSIs are therefore currently in
clinical trials as anticancer drugs, but specific pharmacologic
and molecular properties are still being investigated.
Because little is known about which GSIs will be the most
advantageous in the clinic, it is important to understand
structural and biochemical differences between specific
compounds. Han and colleagues used the Z-LeuLeuNleu-
CHO GSI, which is a derivative of the proteasome inhibitor
MG-132. The structure of MG-132 is Z-LeuLeuLeu-CHO.
GSI-I is very close structurally, differing only by a single
norleucine substitution: Z-LeuLeuNorLeu-CHO. Treatment
with two structurally similar drugs targeted at different
enzymes – that is, γ-secretase or the proteasome – could
therefore be anticipated to inherently have shared effects,
which could account for the results on the proteasome seen
by GSI-I.
Furthermore, current GSIs that are being used in clinical trials
are a new line of medicinally and structurally modified
chemical molecules that could show different effects. DAPT
and L-685,458 GSIs, which were used in Han and
colleagues’ article, are not used in current trials and are
structurally unique. Structurally modified GSIs are still being
investigated and could provide evidence for cellular death via
inhibition of the Notch pathway independent of the
proteasome. Understanding these key properties may lead to
better therapeutic targeting. Studying the effect of these new
classes of GSIs in clinical trials on proteasome activity could
prove very interesting.
In conclusion, in the present article we comment that
Z-LeuLeuLeu-CHO is a derivative of a proteasomal inhibitor,
which could inherently have shared effects; that current GSIs
used in clinical trials are structurally unique and their effects
on the proteasome are as yet unknown; and that the level of
proteasomal activity, which could differ between breast
cancer subtypes, may play a critical role by which GSI-I
functions to inhibit growth. In summary, Han and colleagues
beg the intriguing question of whether proteasome inhibitors
independently or in combination with GSIs or with current
chemotherapeutic agents provide novel and exciting
therapeutic strategies against breast cancer.
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